Anti-Angiogenic Effect of Bortezomib in Patients with Multiple Myeloma

Publisher： Karger

E-ISSN： 1421-9662|114|3|170-173

ISSN： 0001-5792

Source： Acta Haematologica, Vol.114, Iss.3, 2005-10, pp. : 170-173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 314-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effects of bortezomib on bone disease in patients with multiple myeloma

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 618-623

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antiangiogenic Therapy in Multiple Myeloma

By  

Acta Haematologica, Vol. 106, Iss. 4, 2002-01 ,pp. : 208-213

Karger

Access to resources Recommend Favorite

Unusual Discordant Responses in Two Multiple Myeloma Patients during Bortezomib Treatment

By  

Oncology Research and Treatment, Vol. 31, Iss. 1-2, 2008-01 ,pp. : 45-47

Karger

Access to resources Recommend Favorite

Immortal time bias and reverse causality in retrospective analysis: Comment on “effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib–melphalan–prednisone in the phase III VISTA study”

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 8, 2015-08 ,pp. : E146-E146

John Wiley & Sons Inc

Access to resources Recommend Favorite